Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Evofem Biosciences, Inc. | neot-ex991_6.htm |
| EX-99.2 - EX-99.2 - Evofem Biosciences, Inc. | neot-ex992_7.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2016
NEOTHETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-36754 |
|
20-8527075 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
9171 Towne Centre Drive, Suite 270, San Diego, CA 92122
(Address of principal executive offices, with zip code)
(858) 750-1008
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01Regulation FD Disclosure.
A copy of a slide presentation that Neothetics, Inc. (NASDAQ: NEOT) (the “Company”) intends to present to investors is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 8.01Other Events.
On March 28, 2016, the Company provided a business update, including future plans for development of its lead asset LIPO-202.
The press release dated March 28, 2016 providing the business update is furnished hereto as Exhibit 99.2.
|
Item 9.01. |
Financial Statements and Exhibits |
(d) Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Neothetics, Inc. Investor Presentation |
|
99.2 |
|
Press Release, dated March 28, 2016. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOTHETICS, INC.
|
Date: March 28, 2016 |
By:/s/ Susan A. Knudson |
Susan A. Knudson
Chief Financial Officer
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Neothetics, Inc. Investor Presentation |
|
99.2 |
|
Press Release, dated March 28, 2016. |